All Stories

  1. Tralokinumab efficacy in a case of dupilumab‐resistant severe atopic dermatitis complicated by eczema herpeticum
  2. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology ( EADV )
  3. Lepromatous leprosy presenting with erythema nodosum leprosum mimicking Bechet's disease
  4. Severe bullous pemphigoid following Covid‐19 vaccination resistant to rituximab and successfully treated with dupilumab
  5. Rituximab in Mucous Membrane Pemphigoid: A Monocentric Retrospective Study in 10 Patients with Severe/Refractory Disease
  6. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology ( EADV )
  7. Sweet Syndrome Following SARS-CoV2 Vaccination
  8. Development and optimisation of biopharmaceutical properties of a new microemulgel of cannabidiol for locally-acting dermatological delivery
  9. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)
  10. Dupilumab for the treatment of recalcitrant eosinophilic dermatosis of haematologic malignancy
  11. The Role of TRPA1 in Skin Physiology and Pathology
  12. T-Cell Response in Dermatitis Herpetiformis: May Epidermal Transglutaminase Play a Role in Predicting Clinical Relapse?
  13. Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease
  14. Cutaneous eruptions associated with haematologic malignancies: the need for a unifying nomenclature
  15. Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study
  16. T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum
  17. A fatal case of hidradenitis suppurativa associated with sepsis and squamous cell carcinoma
  18. Docetaxel-induced-like subacute cutaneous lupus erythematosus
  19. Corrigendum
  20. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum
  21. The diagnosis and treatment of dermatitis herpetiformis
  22. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group
  23. A case of rupioid psoriasis exacerbated by systemic glucocorticosteroids
  24. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris
  25. Regulatory T cells as well as IL-10 are reduced in the skin of patients with dermatitis herpetiformis
  26. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome
  27. Dermatitis Herpetiformis: Not Only in Adults
  28. Skin manifestations of celiac disease: not always dermatitis herpetiformis
  29. Rowell syndrome: does it exist?
  30. Regulatory T cells in skin lesions and blood of patients with bullous pemphigoid
  31. Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease — Dermatitis herpetiformis
  32. Linear Immunoglobulin A Bullous Dermatosis: Need for an Agreement on Diagnostic Criteria
  33. Cutaneous lupus erythematosus: First multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)
  34. A further case of subacute prurigo-like linear IgA bullous dermatosis: growing evidence of a new subset
  35. Hailey-Hailey disease treated with methotrexate
  36. Etanercept Downregulates the Th17 Pathway and Decreases the IL-17+/IL-10+ Cell Ratio in Patients with Psoriasis Vulgaris
  37. Circulating CD4+ CD25brightFOXP3+ regulatory T-cells are significantly reduced in bullous pemphigoid patients
  38. Newly Described Clinical and Immunopathological Feature of Dermatitis Herpetiformis
  39. Dermatitis herpetiformis: Novel advances and hypotheses
  40. Dermatitis Herpetiformis: From the Genetics to the Development of Skin Lesions
  41. Celiac Disease and Dermatologic Manifestations: Many Skin Clue to Unfold Gluten-Sensitive Enteropathy
  42. The last word on the so-called ‘Rowell’s syndrome’?
  43. Gluten-Free Diet in Patients With Dermatitis Herpetiformis: Not Only a Matter of Skin
  44. Comment on "Dermatitis Herpetiformis Sera or Goat Anti-Transglutaminase-3 Transferred to Human Skin-Grafted Mice Mimics Dermatitis Herpetiformis Immunopathology"
  45. A case of lichenoid drug eruption associated with subcutaneous immunoglobulin therapy
  46. Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus
  47. Repigmentation of hair after latanoprost therapy
  48. Characterization of regulatory T cells in patients with dermatomyositis
  49. Effects of tacrolimus ointment on Toll-like receptors in atopic dermatitis
  50. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea
  51. Immunosuppressive therapy may affect the number of circulating regulatory cells in systemic sclerosis: Pay attention to the patient selection criteria
  52. Linear immunoglobulin A bullous dermatosis
  53. Plasma levels of metalloproteinase-9 are elevated in patients with chronic autoimmune urticaria
  54. Antilaminin-1 antibodies in cutaneous lupus erythematosus patients
  55. Guidelines for the diagnosis and treatment of dermatitis herpetiformis
  56. A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis
  57. Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial
  58. Serum interleukin-13 levels are increased in patients with Stevens–Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme
  59. FoxP3-expressing T regulatory cells in atopic dermatitis lesions
  60. The CD40/CD40 ligand system is involved in the pathogenesis of pemphigus
  61. Chronic autoimmune urticaria in a patient with multiple piloleiomyomas
  62. Cutis marmorata telangiectatica congenita and chronic autoimmune urticaria in a young man
  63. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study
  64. Serum Levels of the Th1 Promoter IL-12 and the Th2 Chemokine TARC Are Elevated in Erythema Multiforme and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Correlate with Soluble Fas Ligand Expression
  65. Bullous pemphigoid initially localized around a urostomy
  66. Expression of adhesion molecules in atopic dermatitis is reduced by tacrolimus, but not by hydrocortisone butyrate: a randomized immunohistochemical study
  67. An unusual cause of gastrointestinal bleeding in a young girl
  68. Ulcerative Carcinoma of the Breast With Zosteriform Skin Metastases
  69. The Effects of Tacrolimus Ointment on Regulatory T Lymphocytes in Atopic Dermatitis
  70. Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum
  71. A Case of Nodular Scleroderma
  72. A Case of Lichenoid Drug Eruption Associated with Sildenafil Citratus
  73. Radiation Therapy as a Trigger Factor for Initially Localized Bullous Pemphigoid
  74. Serological detection of eotaxin, IL-4, IL-13, IFN-γ, MIP-1α, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria
  75. Chronic Idiopathic and Chronic Autoimmune Urticaria: Clinical and Immunopathological Features of 68 Subjects
  76. Dermatite atopica: diagnostica in vitro